Literature DB >> 10585234

Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.

J M Sarciaux1, S Mansour, M J Hageman, S L Nail.   

Abstract

The objective of this study was to identify critical formulation and processing variables affecting aggregation of bovine IgG during freeze-drying when no lyoprotective solute is used. Parameters examined were phosphate buffer concentration and counterion (Na versus K phosphate), added salts, cooling rate, IgG concentration, residual moisture level, and presence of a surfactant. No soluble aggregates were detected in any formulation after either freezing/thawing or freeze-drying. No insoluble aggregates were detected in any formulation after freezing, but insoluble aggregate levels were always detectable after freeze-drying. The data are consistent with a mechanism of aggregate formation involving denaturation of IgG at the ice/freeze-concentrate interface which is reversible upon freeze-thawing, but becomes irreversible after freeze-drying and reconstitution. Rapid cooling (by quenching in liquid nitrogen) results in more and larger aggregates than slow cooling on the shelf of the freeze-dryer. This observation is consistent with surface area measurements and environmental electron microscopic data showing a higher surface area of freeze-dried solids after fast cooling. Annealing of rapidly cooled solutions results in significantly less aggregation in reconstituted freeze-dried solids than in nonannealed controls, with a corresponding decrease in specific surface area of the freeze-dried, annealed system. Increasing the concentration of IgG significantly improves the stability of IgG against freeze-drying-induced aggregation, which may be explained by a smaller percentage of the protein residing at the ice/freeze-concentrate interface as IgG concentration is increased. A sodium phosphate buffer system consistently results in more turbid reconstituted solids than a potassium phosphate buffer system at the same concentration, but this effect is not attributable to a pH shift during freezing. Added salts such as NaCl or KCl contribute markedly to insoluble aggregate formation. Both sodium and potassium chloride contribute more to turbidity of the reconstituted solid than either sodium or potassium phosphate buffers at similar ionic strength, with sodium chloride resulting in a substantially higher level of aggregates than potassium chloride. At a given cooling rate, the specific surface area of dried solids is approximately a factor of 2 higher for the formulation containing sodium chloride than the formulation containing potassium chloride. Turbidity is also influenced by the extent of secondary drying, which underscores the importance of minimizing secondary drying of this system. Including a surfactant such as polysorbate 80, either in the formulation or in the water used for reconstitution, decreased, but did not eliminate, insoluble aggregates. There was no correlation between pharmaceutically acceptability of the freeze-dried cake and insoluble aggregate levels in the reconstituted product.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585234     DOI: 10.1021/js980383n

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Scientific considerations for generic synthetic salmon calcitonin nasal spray products.

Authors:  Sau L Lee; Lawrence X Yu; Bing Cai; Gibbes R Johnsons; Amy S Rosenberg; Barry W Cherney; Wei Guo; Andre S Raw
Journal:  AAPS J       Date:  2010-10-30       Impact factor: 4.009

2.  Freeze-drying of proteins from a sucrose-glycine excipient system: effect of formulation composition on the initial recovery of protein activity.

Authors:  Wei Liu; D Q Wang; Steven L Nail
Journal:  AAPS PharmSciTech       Date:  2005-09-30       Impact factor: 3.246

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  Characterization of the native and denatured herceptin by enzyme linked immunosorbent assay and quartz crystal microbalance using a high-affinity single chain fragment variable recombinant antibody.

Authors:  Yuqin Shang; Ray Mernaugh; Xiangqun Zeng
Journal:  Anal Chem       Date:  2012-09-13       Impact factor: 6.986

5.  Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.

Authors:  Srivalli Telikepalli; Ozan S Kumru; Jae Hyun Kim; Sangeeta B Joshi; Kristin B O'Berry; Angela W Blake-Haskins; Melissa D Perkins; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-12-17       Impact factor: 3.534

6.  Freeze-concentration separates proteins and polymer excipients into different amorphous phases.

Authors:  K Izutsu; S Kojima
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

7.  Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying.

Authors:  True L Rogers; Andrew C Nelsen; Marazban Sarkari; Timothy J Young; Keith P Johnston; Robert O Williams
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

8.  Effect of the Freezing Step in the Stability and Bioactivity of Protein-Loaded PLGA Nanoparticles Upon Lyophilization.

Authors:  Pedro Fonte; Fernanda Andrade; Cláudia Azevedo; João Pinto; Vítor Seabra; Marco van de Weert; Salette Reis; Bruno Sarmento
Journal:  Pharm Res       Date:  2016-07-21       Impact factor: 4.200

9.  Nanostructured thin film polymer devices for constant-rate protein delivery.

Authors:  Daniel A Bernards; Kevin D Lance; Natalie A Ciaccio; Tejal A Desai
Journal:  Nano Lett       Date:  2012-09-19       Impact factor: 11.189

10.  Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations.

Authors:  Andrea Hawe; Vasco Filipe; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-12-30       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.